The role of carnitine supplementation during valproic acid therapy

OBJECTIVE: To review the pathophysiology and significance of valproic acid-induced carnitine deficiency; to present and evaluate the literature pertaining to carnitine supplementation in pediatric patients receiving valproic acid; and to present the consensus guidelines for carnitine supplementation during valproic acid therapy. DATA SOURCES: A MEDLINE search (1966-December 1998) restricted to English-language literature, using MeSH headings of carnitine and valproic acid, was conducted to identify clinically relevant articles. Selected articles and references focusing on the pediatric population were included for review. DATA EXTRACTION: Study design, patient population, methods, and clinical outcomes were evaluated. DATA SYNTHESIS: Valproic acid, a widely used antiepileptic agent in the pediatric population, is limited by a 1/800 incidence of fatal hepatotoxicity in children under the age of two years. Carnitine is an essential amino acid necessary in beta-oxidation of fatty acids and energy production in cellular mitochondria. It has been hypothesized that valproic acid may induce a carnitine deficiency in children and cause nonspecific symptoms of deficiency, hepatotoxicity, and hyperammonemia. Relevant published case reports and trials studying this relationship are evaluated, and a consensus statement by the Pediatric Neurology Advisory Committee is reviewed. CONCLUSIONS: Despite the lack of prospective, randomized clinical trials documenting efficacy of carnitine supplementation in preventing valproic acid-induced hepatotoxicity, the few limited studies available have shown carnitine supplementation to result in subjective and objective improvements along with increases in carnitine serum concentrations in patients receiving valproic acid. The Pediatric Neurology Advisory Committee in 1996 provided more concrete indications on the role of carnitine in valproic acid therapy, such as valproic acid overdose and valproic acid-induced hepatotoxicity. Carnitine was strongly recommended for children at risk of developing a carnitine deficiency. Although carnitine has been well tolerated, future studies are needed to evaluate the efficacy of prophylactic carnitine supplementation for the prevention of hepatotoxicity.

This article has been cited by other articles:

				Y. Chan, M. Tse, and F. Lau Two cases of valproic acid poisoning treated with l-carnitine Human and Experimental Toxicology, December 1, 2007; 26(12): 967 - 969. [Abstract] [PDF]

				J. Wadzinski, R. Franks, D. Roane, and M. Bayard Valproate-associated Hyperammonemic Encephalopathy J Am Board Fam Med, September 1, 2007; 20(5): 499 - 502. [Abstract] [Full Text] [PDF]

				R. B. Carr and K. Shrewsbury Hyperammonemia Due to Valproic Acid in the Psychiatric Setting Am J Psychiatry, July 1, 2007; 164(7): 1020 - 1027. [Full Text] [PDF]

				C. A. Ott, N. Campbell, and E. A. Dworek Valproic Acid Induced Hyperammonemia in a Patient With Schizoaffective Disorder Journal of Pharmacy Practice, February 1, 2007; 20(1): 82 - 92. [Abstract] [PDF]

				E. Rytting and K. L. Audus Novel Organic Cation Transporter 2-Mediated Carnitine Uptake in Placental Choriocarcinoma (BeWo) Cells J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 192 - 198. [Abstract] [Full Text] [PDF]

				K. Lahjouji, I. Elimrani, J. Lafond, L. Leduc, I. A. Qureshi, and G. A. Mitchell L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2 Am J Physiol Cell Physiol, August 1, 2004; 287(2): C263 - C269. [Abstract] [Full Text] [PDF]

				I. Elimrani, K. Lahjouji, E. Seidman, M.-J. Roy, G. A. Mitchell, and I. Qureshi Expression and localization of organic cation/carnitine transporter OCTN2 in Caco-2 cells Am J Physiol Gastrointest Liver Physiol, May 1, 2003; 284(5): G863 - G871. [Abstract] [Full Text] [PDF]

				P. S. Phillips, R. H. Haas, S. Bannykh, S. Hathaway, N. L. Gray, B. J. Kimura, G. D. Vladutiu, J. D.F. England, and the Scripps Mercy Clinical Research Center* Statin-Associated Myopathy with Normal Creatine Kinase Levels Ann Intern Med, October 1, 2002; 137(7): 581 - 585. [Abstract] [Full Text] [PDF]

				N. Ubeda, E. Alonso-Aperte, and G. Varela-Moreiras Acute Valproate Administration Impairs Methionine Metabolism in Rats J. Nutr., September 1, 2002; 132(9): 2737 - 2742. [Abstract] [Full Text] [PDF]